1. Home
  2. CVS
  3. Earnings

AI Earnings Predictions for CVS Health Corporation (CVS)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

BUY

1-Day Prediction

+1.07%

$92.33

100% positive prob.

5-Day Prediction

+3.31%

$94.38

100% positive prob.

20-Day Prediction

+3.21%

$94.28

95% positive prob.

Price at prediction: $91.35 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 BUY +1.07% +3.31% +3.21% 100.0% Pending
Q2 2026 SELL -1.79% -3.01% -6.21% 100.0% Pending
Q1 2026 BUY +1.14% +1.95% +2.36% 100.0% +12.88%
Q4 2025 SELL -1.79% -3.01% -6.21% 100.0% +2.71%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 4, 2026 · 100% conf.

AI Prediction BUY

1D

+1.07%

$92.33

Act: +1.71%

5D

+3.31%

$94.38

20D

+3.21%

$94.28

Price: $91.35 Prob +5D: 100% AUC: 1.000
0000064803-26-000107

EX-99.1

2 cvs_ex99x1q3-26.htm

EX-99.1

Document

Exhibit 99.1

CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2026 RESULTS

AND RAISES FULL-YEAR 2026 GUIDANCE

•Third quarter total revenues increased to $108.4 billion, up 5.4% year-over-year

•Third quarter GAAP diluted EPS of $1.68 and Adjusted EPS of $2.09

•Generated year-to-date cash flow from operations of $15.3 billion

•Raising full-year 2026 guidance:

◦GAAP diluted EPS guidance to at least $6.98 from a range of $6.84 to $7.04

◦Adjusted EPS guidance to at least $8.20 from a range of $7.90 to $8.10

◦Cash flow from operations guidance to at least $15.5 billion from at least $11.5 billion

WOONSOCKET, RHODE ISLAND, November 4, 2026 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2026.

“Our colleagues build trust every day through delivering quality health care rooted in our purpose - to simplify health care one person, one family and one community at a time. Through their continued dedication, each of our businesses delivered another quarter of strong results. We continue to advance our strategy by improving the consumer experience, lowering health care costs, and connecting care for the people we serve.”

- David Joyner, CVS Health Chairman and CEO

Three Months Ended September 30, Year Ending

December 31,

In billions, except per share amounts 20262025 2026 Projected

Total revenues $108.4 $102.9 At least $420.0

Diluted earnings (loss) per share $1.68 $(3.13) At least $6.98

Adjusted EPS (2) $2.09 $1.60 At least $8.20

Third quarter GAAP diluted earnings per share of $1.68 increased from a loss per share of $3.13 in the prior year, reflecting the absence of a $5.7 billion goodwill impairment charge recorded in the third quarter of 2025. Adjusted EPS of $2.09 increased from $1.60 in the prior year, primarily due to improved adjusted operating income in the Health Care Benefits segment, reflecting continued execution of its margin recovery plan.

The Company is increasing its full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.

1

Consolidated third quarter results

Three Months Ended September 30,Nine Months Ended September 30,

In millions, except per share amounts20262025Change20262025Change

Total revenues $108,399 $102,871 $5,528 $314,921 $296,374 $18,547

Operating income (loss)3,566 (3,207)6,773 12,949 2,548 10,401

Adjusted operating income (1) 4,194 3,459 735 14,501 11,846 2,655

Net income (loss)2,171 (3,990)6,161 8,123 (1,195)9,318

Diluted earnings (loss) per share$1.68 $(3.13)$4.81 $6.29 $(0.93)$7.22

Adjusted EPS (2) $2.09 $1.60 $0.49 $7.24 $5.66 $1.58

For the three months ended September 30, 2026 compared to the prior year:

•Total revenues increased 5.4% primarily driven by growth in the Health Services and Health Care Benefits segments.

•During the three months ended September 30, 2026, the Company generated operating income of $3.6 billion compared to an operating loss of $3.2 billion in the prior year. The difference was primarily driven by the absence of the $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit recorded in the prior year and the increase in adjusted operating income described below.

•Adjusted operating income increased 21.2% primarily driven by increases across all operating segments. See pages 3 through 5 for additional discussion of the adjusted operating income performance of the Company’s segments.

Operational Updates

•More than 69 percent of Aetna® Medicare Advantage members are in 2027 plans rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services. These results position Aetna second among large, publicly traded Medicare Advantage organizations in the Star Ratings program. For the third consecutive year, Aetna’s commitment to care has driven strong performance across various clinical quality, preventive care and member experience measures.

•CVS Health continues to lead the industry through enhancements to its direct-to-consumer weight management offerings to improve access, affordability, care and support for GLP-1 medications. CVS Pharmacy offers all FDA-approved GLP-1s. Through its integrated offerings, CVS Health can combine a MinuteClinic digital weight loss visit with a licensed clinician, same-day medication pickup at 9,000 local CVS Pharmacy locations, and in-person pharmacist support in one connected experience, with no membership or recurring monthly fee.

•Health100™, a CVS Health subsidiary, earned the CARIN Code of Conduct for Consumer-Facing Applications Accreditation from DirectTrust® for the Health100 mobile app. Health100 provides consumers with cost transparency and the ability to reduce

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 5, 2026 · 100% conf.

AI Prediction SELL

1D

-1.79%

$97.34

Act: -2.93%

5D

-3.01%

$96.13

20D

-6.21%

$92.96

Price: $99.12 Prob +5D: 0% AUC: 1.000
0000064803-26-000097

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1786388695.cf96ca5f

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K BUY

May 6, 2026 · 100% conf.

AI Prediction BUY

1D

+1.14%

$87.85

Act: +0.58%

5D

+1.95%

$88.55

Act: +12.88%

20D

+2.36%

$88.91

Act: +9.16%

Price: $86.86 Prob +5D: 100% AUC: 1.000
0000064803-26-000051

EX-99.1

2 cvs_ex99x1q1-26.htm

EX-99.1

Document

Exhibit 99.1

CVS HEALTH CORPORATION REPORTS STRONG FIRST QUARTER 2026 RESULTS

AND RAISES FULL-YEAR 2026 GUIDANCE

•First quarter total revenues increased to $100.4 billion, up 6.2% year-over-year

•First quarter GAAP diluted EPS of $2.30 and Adjusted EPS of $2.57

•Raising full-year 2026 guidance:

◦GAAP diluted EPS guidance range to $6.24 to $6.44 from $5.94 to $6.14

◦Adjusted EPS guidance range to $7.30 to $7.50 from $7.00 to $7.20

◦Cash flow from operations guidance to at least $9.5 billion from at least $9.0 billion

WOONSOCKET, RHODE ISLAND, May 6, 2026 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended March 31, 2026.

“CVS Health continues to provide what people want most from health care: a connected, convenient, cost-effective engagement experience across our unique collection of businesses. We build trust every day in communities across the country by providing better access, affordability and care to nearly 185 million people. Our positive performance is driven by strong execution across our enterprise. We will continue to build momentum through delivering on our strategy and a steadfast focus on our purpose - to simplify health care one person, one family and one community at a time.”

- David Joyner, CVS Health Chairman and CEO

Three Months Ended March 31, Year Ending

December 31,

In billions, except per share amounts 20262025 2026 Projected

Total revenues $100.4 $94.6 At least $405.0

Diluted earnings per share $2.30 $1.41 $6.24-$6.44

Adjusted EPS (2) $2.57 $2.25 $7.30-$7.50

Cash flow from operations $4.2 $4.6 At least $9.5

First quarter GAAP diluted EPS of $2.30 increased from $1.41 in the prior year. Adjusted EPS of $2.57 increased from $2.25 in the prior year, primarily due to improved adjusted operating income in the Health Care Benefits segment, reflecting continued execution on the Health Care Benefits segment margin recovery plan.

The Company is increasing its full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.

1

Consolidated first quarter results

Three Months Ended March 31,

In millions, except per share amounts20262025Change

Total revenues $100,426 $94,588 $5,838

Operating income 4,680 3,374 1,306

Adjusted operating income (1) 5,150 4,579 571

Net income 2,957 1,782 1,175

Diluted earnings per share $2.30 $1.41 $0.89

Adjusted EPS (2) $2.57 $2.25 $0.32

For the three months ended March 31, 2026 compared to the prior year:

•Total revenues increased 6.2% driven by revenue growth across all operating segments.

•Operating income increased 38.7% primarily due to the increase in adjusted operating income described below, as well as the absence of a $387 million legacy litigation charge and a $247 million pre-tax loss on the wind down and sale of Accountable Care assets, both recorded in the prior year.

•Adjusted operating income increased 12.5% primarily driven by an increase in the Health Care Benefits segment. See pages 3 through 5 for additional discussion of the adjusted operating income performance of the Company’s segments.

Operational Updates

•The release of the U.S. Centers for Medicare & Medicaid Services’ improved Medicare Advantage final rate notice and home health assessment policy enable strong member service and more performance clarity for 2027.

•Aetna® announced significant progress in streamlining the prior authorization reform, exceeding industry commitments across all benchmarks: standardizing data requirements for 88% of prior authorization volume, approving more than 95% of eligible prior authorizations within 24 hours, processing 83% of prior authorizations in real time and eliminating more than 1 million provider calls through automation and digital tools.

•CVS Health announced Health100, a health technology services subsidiary, which will use Google Cloud’s AI technologies to deliver a fully integrated health care engagement platform to provide a connected, proactive and personalized experience for American consumers.

•CVS Pharmacy® continues to increase community access to care, including through the unveiling of small pharmacy-focused locations in 2026.

2

Health Care Benefits segment

The Health Care Benefits segment offers a full range of insured and self-insured (“ASC”) medical, pharmacy, dental and behavioral health products and services. The segment results for the three months ended March 31, 2026 and 2025 were as follows:

Three Months Ended March 31,

In millions, except percentages20262025Change

Total revenues$35,971$34,810$1,161

Adjusted operating income (1) 3,0411,9931,048

Medical benefit ratio (“MBR”) (3) 84.6 %87.3 %(2.7)%

Medical membership (4) 26.027.1(1.1)

About CVS Health Corporation (CVS) Earnings

This page provides CVS Health Corporation (CVS) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on CVS's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: